Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association Scientific Sessions

Rona Therapeutics New York China California

Single dose of RN0191 achieved up to 95% individual maximum and 87% mean maximum PCSK9 reduction, and up to 74% individual maximum and 56% mean maximal LDL-C loweringRobust and sustainable treatment effects support at least bi-annual dosing regimenBest-in-class potential of novel PCSK9 siRNA RN0191 supports further development as single agent or combination to further reduce atherosclerosis cardiovascular risk View original content:https://www.prnewswire.co.uk/news-releases/rona-therapeutics-presented-positive-phase-1-results-of-rn0191-a-novel-sirna-therapy-targeting-pcsk9-at-the-2024-american-heart-association-aha-scientific-sessions-302307711.html